DOV Stresses “Residual Value” Of Bicifadine In Chronic Pain Despite Initial Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm had planned an NDA filing in the first half of 2007 for use of the non-opioid analgesic for chronic low back pain.